Bridgeway Capital Management, LLC Curis Inc Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $177,600 - $3.6 Million	240,000 Added 1437.13%	256,700 $180,000
Q2 2022 Aug 15, 2022	BUY	$0.71 - $2.43 $11,857 - $40,581	16,700 New	16,700 $16,000
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $138,600 - $307,800	-60,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$8.78 - $12.8 $865,181 - $1.26 Million	-98,540 Reduced 62.15%	60,000 $679,000
Q4 2020 Feb 16, 2021	SELL	$1.08 - $8.2 $93,744 - $711,759	-86,800 Reduced 35.38%	158,540 $1.3 Million
Q2 2020 Aug 14, 2020	SELL	$0.63 - $1.7 $47,250 - $127,500	-75,000 Reduced 23.41%	245,340 $297,000
Q4 2019 Feb 14, 2020	BUY	$1.36 - $2.44 $283,016 - $507,764	208,100 Added 185.41%	320,340 $545,000
Q2 2019 Aug 14, 2019	BUY	$1.36 - $2.35 $136,000 - $235,000	100,000 Added 816.99%	112,240 $209,000
Q4 2018 Feb 14, 2019	SELL	$0.62 - $2.25 $110,918 - $402,525	-178,900 Reduced 93.6%	12,240 $8,000
Q2 2018 Aug 14, 2018	BUY	$1.73 - $3.35 $330,672 - $640,319	191,140 New	191,140 $331,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.